title: Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven).
abstract: Bleeding episodes in haemophilia A and B inhibitor patients are now frequently treated with recombinant activated factor VII (NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark). Until now, the FVII:C coagulation assay has been used to monitor NovoSeven-mediated coagulation. However, a new assay (Staclot VIIa-rTF, Diagnostica Stago, France) has been designed to specifically detect activated factor (F)VII. Replacement of the buffer supplied by the manufacturer with a PIPES buffer containing BSA (modified FVIIa assay), resulted in a linear standard curve, greater sample stability and a reduced coefficient of variation. The FVII:C assay and the modified FVIIa assay were compared in a recovery experiment using the International FVIIa standard No 89/688(IS). Recovery of FVIIa was 93-97% for the modified FVIIa assay and 91-115% for the FVII:C assay. However, because samples in the FVII:C assay were not parallel to the standard curve, confidence limits for recovery were as wide as 67-130% compared with 92-106% for the FVIIa assay. In conclusion, a modified version of the Staclot VIIa-rTF assay, suitable for monitoring treatment with NovoSeven, even at low concentrations, has been developed. It provides an alternative to the FVII:C assay, which is not suitable for monitoring FVIIa at low concentrations.
authors.affiliation: Immunochemistry, Novo Nordisk A/S, Bagsvaerd, Denmark. MJ@novo.dk
authors.forename: M
authors.initials: M
authors.lastname: Johannessen
authors.forename: G
authors.initials: G
authors.lastname: Nielsen
authors.forename: O
authors.initials: O
authors.lastname: Nordfang
mesh_terms: D001681:Biological Assay / Q000379:methods; D001777:Blood Coagulation; D016903:Drug Monitoring / Q000379:methods; D005167:Factor VII / Q000378:metabolism*; D015942:Factor VIIa / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011486:Protein C / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D011486:Protein C; D011994:Recombinant Proteins; D005167:Factor VII; D015942:Factor VIIa